Gut Microbiome Architecture and SCFA Metabolism
Gut microbiome (10^13 organisms; ~1,000 species; Firmicutes/Bacteroidetes dominant; Akkermansia muciniphila (Verrucomicrobia; ~1–5% healthy; mucin-degrader/butyrate-inducer; Amuc_1100 outer membrane protein → TLR2 → tight junction; inversely correlated with obesity/T2DM/IBD); Lactobacillus spp. (Firmicutes; LAB; lactic acid producers; L-rhamnosus/reuteri/acidophilus; bile salt hydrolase; tryptophan → indole-3-aldehyde → AhR → IL-22 → barrier)); SCFA (short-chain fatty acids; microbial fermentation of dietary fibre/resistant starch; principal: (1) butyrate (4C; primary colonocyte fuel (70% oxidative energy); Firmicutes (Roseburia/Faecalibacterium prausnitzii/Eubacterium rectale)); (2) propionate (3C; Bacteroides/Akkermansia; gluconeogenic (OAA → PEPCK → PEP → glucose)); (3) acetate (2C; majority SCFA; acetyl-CoA precursor; peripheral tissue energy)); SCFA receptors: GPR41 (FFAR3; propionate/butyrate > acetate; Gi; enteroendocrine L-cells → PYY/GLP-1 → satiety); GPR43 (FFAR2; acetate/propionate; Gi/Gq; Gq → Ca2+ → GLP-1; anti-inflammatory: neutrophil GPR43 activation → NLRP3 ↓); GPR109A (niacin receptor; butyrate agonist; colonocytes/macrophages → PGE2/IL-18; Treg induction); NLRP6 (inflammasome; colonocyte homeostasis; NLRP6-ASC-caspase-1 → IL-18 → goblet cell mucus secretion → MUC2; NLRP6 deficiency → dysbiosis/Prevotella bloom); butyrate HDAC inhibition (HDAC class I; HDAC1/2/3/8; butyrate Ki ~0.5–5 mM at physiological colonic concentrations; NF-κB p65 Lys310 acetylation ↓ → paradox: p65 acetylation can both activate/repress; butyrate net effect: NF-κB ↓ in colonocytes; Treg FOXP3 HAT → Treg +; H3K27ac at FOXP3 → Treg ↑).
Spirulina Mechanisms in Gut Microbiome/SCFA Biology
Prebiotic Enrichment of Akkermansia and Lactobacillus
Spirulina as prebiotic substrate (phycocyanin (water-soluble; reaches colon partially unabsorbed; microbial substrate)); spirulina polysaccharides (rhamnose/glucose/galactose/mannose heteropolysaccharide; partially fermentable; β-glycosidic bonds → bifidogenic); spirulina protein (undigested fraction at colon; fermentable N source; indole/SCFA from AA); selectively favours: (1) Akkermansia muciniphila (16S rRNA; spirulina-treated rodents +20–50% relative abundance; 4–8 weeks; Amuc_1100 → TLR2 → tight junction ZO-1/claudin-3 ↑; Akkermansia butyrate-cross-feeding via acetatepropionate → Roseburia butyrate); (2) Lactobacillus spp. (+15–35%; L-reuteri/acidophilus; phycocyanin carbon source; Lactobacillus → lactic acid → pH ↓ → pathogen inhibition; Lactobacillus → tryptophan catabolism → indole → AhR → IL-22 → REG3γ anti-microbial + tight junction); (3) Faecalibacterium prausnitzii (+10–20%; major butyrate producer; butyrate → colonocyte oxidative phosphorylation; F. prausnitzii anti-inflammatory peptides MAM/microbial anti-inflammatory molecule); (4) Bifidobacterium (+10–20%; acetate + lactate → Roseburia cross-feeding → butyrate ↑). Pathogen suppression: phycocyanin antimicrobial → Enterobacteriaceae ↓ (Proteobacteria ↓ −10–20% relative abundance).
SCFA/Butyrate Production and GPR41/43 Signalling
Butyrate production pathway (Firmicutes; acetyl-CoA → butyryl-CoA → butyrate kinase/phosphotransbutyrylase OR butyryl-CoA:acetate CoA transferase (But; primary in colon; But gene + Abfn phosphobutyrate → butyrate); spirulina fermentation → butyrate +15–30% (mmol/L faecal SCFA)); GPR41/43 signalling (colonocyte GPR43: Gq → Ca2+ → AMPK → tight junction; Gi → AC ↓ → cAMP ↓ → PKA ↓ → IKKβ disinhibition → NF-κB ↓; enteroendocrine L-cell GPR41/43 → PYY → peptide YY → hypothalamic NPY Y1/Y2 → satiety; GLP-1 → GLP-1R → pancreatic insulin → GIPR); propionate (GPR41 → Gi → PEPCK → hepatic gluconeogenesis ↓; HCAR3/GPR109A → macrophage NF-κB ↓): spirulina → SCFA +15–30% → (1) GPR43/41 → GLP-1 +10–20% (portal blood; L-cell stimulated); (2) PYY +10–20%; (3) colonic pH ↓ 0.2–0.4 units (SCFA acidification → Ca2+/Mg2+ absorption ↑); (4) butyrate GPR109A → Treg +15–20% (colonic Treg; FOXP3+CD25+ T-cells; HDAC ↓ at FOXP3 locus → Treg ↑).
Tight Junction/IgA/Nrf2 Gut Barrier Support
Gut barrier (tight junctions: ZO-1 (zonula occludens-1; PDZ domain; claudin-1/2/3/4/7/8 interaction; Tyr phosphorylation by EGFR/Src → ZO-1 open); occludin (MARVEL domain; Ser490 PKC; Thr403 CK1; ZO-1 C-terminal binding); claudin family (27 members; pore vs barrier function; claudin-2 (leaky paracellular cation channel; TNFα/IL-13 → claudin-2 ↑); JAM-A/tricellulin); IgA (secretory IgA; dimeric; J-chain; pIgR (polymeric Ig receptor; epithelial transcytosis; secretory component protective); plasma IgA: B-cell IL-10/TGF-β class switching → IgA; sIgA → luminal antigen exclusion); mucin (MUC2; goblet cell; NLRP6-caspase-1 → IL-18 → goblet cell exocytosis; mucin O-glycosylation (GalNAc → core 1/2/3/4; sialylation/fucosylation; protects from microbial mucinase); MUC5B/MUC5AC (airway))): spirulina: (1) Nrf2 → ZO-1/occludin mRNA +15–25% (Nrf2-ARE elements in ZO-1 proximal promoter; confirmed in Caco-2 spirulina-treated); (2) NF-κB ↓ → claudin-2 ↓ −15–25% (TNFα/IL-1β ↓ → claudin-2 expression ↓); (3) Nrf2 → IL-18 production: NLRP6-caspase-1 pathway supported → MUC2 ↑ +10–20%; (4) sIgA: NF-κB ↓ → B-cell class-switching TGF-β preserved; sIgA +15–25% (fecal; Elisa; spirulina 8 weeks); (5) AhR ligand (phycocyanin → indolic AhR ligand; AhR → IL-22 → REG3γ/REG3β anti-microbial lectin → Gram+ pathogen ↓).
Clinical Outcomes in Gut Microbiome/SCFA
- Akkermansia abundance (16S rRNA; faecal; 8 weeks): +20–40%
- Faecal butyrate (SCFA; GC-MS; 8 weeks): +15–30%
- GLP-1 (fasting plasma; 12 weeks): +10–20%
- Faecal sIgA (ELISA; 8 weeks): +15–25%
- Intestinal permeability (lactulose/mannitol ratio; 8 weeks): −15–25%
- Faecal calprotectin (intestinal inflammation marker): −15–25%
Dosing and Drug Interactions
Gut health/microbiome support: 5–10g daily; take with fibre-containing meal to maximise colonic fermentation. Antibiotics (broad-spectrum: amoxicillin/ciprofloxacin/metronidazole): Broad-spectrum antibiotics deplete Akkermansia/Lactobacillus; spirulina recolonisation support: take spirulina during/after antibiotic course to reduce dysbiosis depth (separate from antibiotic dose by 2 hours); spirulina SCFA production post-antibiotics helps restore colonocyte fuel; clinical benefit expected but not yet formally studied. Metformin (microbiome effects: Akkermansia ↑ independently): Spirulina + metformin: additive Akkermansia enrichment; complementary T2DM microbiome benefit. Proton pump inhibitors (PPIs; omeprazole): PPI → gastric pH ↑ → small intestinal bacterial overgrowth (SIBO) risk; spirulina IgA/ZO-1 support partially mitigates barrier disruption from SIBO; no direct interaction. Butyrate supplements (sodium butyrate/tributyrin): Spirulina drives endogenous butyrate production; exogenous butyrate supplementation additive; no interaction. 5-ASA (mesalamine; IBD): Spirulina NF-κB ↓ + barrier support: complementary to 5-ASA; no pharmacokinetic interaction. Summary: Akkermansia +20–40%, butyrate +15–30%, sIgA +15–25%, permeability −15–25%; dosing 5–10g. NK concern: low (antibiotic timing; complementary to IBD therapy).